MetaSight Diagnostics

Company Overview

Snapshot

Founded in April 2020 by Tomer Shlomi, MetaSight Diagnostics operates with 11–50 employees. The company raised $8M across two funding rounds and was acquired by Guardant Health in February 2026.

Business overview

MetaSight Diagnostics develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test, applicable for population-scale screening. Its approach leverages a large clinico multi-OMICS database, generated using its proprietary unbiased metabolomics, lipidomics, and proteomics platform. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Test Diagnostics & Screening.

Strategic signal

MetaSight Diagnostics was acquired by Guardant Health in February 2026 for $59 million, with an option for an additional $90 million. This acquisition highlights the strategic value of MetaSight's liquid biopsy technology and its potential to enhance Guardant Health's diagnostic capabilities, signaling strong market validation for its innovative approach in the health tech and life sciences sector.

Company Intelligence Q&A

When was MetaSight Diagnostics acquired?

MetaSight Diagnostics was acquired by Guardant Health in February 2026.

What was the acquisition amount for MetaSight Diagnostics?

MetaSight Diagnostics was acquired for $59 million, with an option for an additional $90 million.

Which investors participated in MetaSight Diagnostics' Series A funding round in November 2024?

In November 2024, MetaSight Diagnostics raised funding from Saban Ventures and aMoon Fund.

What is MetaSight Diagnostics' core technology?

MetaSight Diagnostics leverages a proprietary unbiased metabolomics, lipidomics, and proteomics platform to generate a clinico multi-OMICS database for diagnostic development.

Who founded MetaSight Diagnostics and when?

MetaSight Diagnostics was founded in April 2020 by Tomer Shlomi.